The Effect of Insurance Expansions on Smoking Cessation Medication Use: Evidence from Recent Medicaid Expansions
We explore the early effects of recent Medicaid expansions on prescriptions and Medicaid payments for evidence-based smoking cessation medications: Zyban, Chantix, and Nicotrol. We estimate differences-in-differences models using data on the universe of prescription medications sold in retail and online pharmacies for which Medicaid was a third-party payer. Our findings suggest that expansions increased smoking cessation prescriptions by 36% and total payments for these medications by 28%. We provide evidence that these payments were financed by Medicaid programs and not patients. Overall our findings suggest that the recent Medicaid expansions allowed low-income smokers to access efficacious cessation medications.
You may purchase this paper on-line in .pdf format from SSRN.com ($5) for electronic delivery.
Document Object Identifier (DOI): 10.3386/w23450